Iotalamic acid

Iotalamic acid
Skeletal formula of iotalamic acid
Space-filling model of the iotalamic acid molecule
Clinical data
Trade namesConray, Glofil-125, Cysto-Conray II, others
Other namesMI-216, iothalamate meglumine, Iothalamic acid (USAN US)
AHFS/Drugs.comConsumer Drug Information
License data
Routes of
administration		Intravascular[1]
ATC code
Legal status
Legal status
Identifiers
  • 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.017.181 Edit this at Wikidata
Chemical and physical data
FormulaC11H9I3N2O4
Molar mass613.916 g·mol−1
3D model (JSmol)
  • CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I
  • InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
  • Key:UXIGWFXRQKWHHA-UHFFFAOYSA-N

Iotalamic acid, sold under the brand name Conray, is an iodine-containing radiocontrast agent. It is available in form of its salts, sodium iotalamate and meglumine iotalamate. It can be given intravenously or intravesically (into the urinary bladder).[1]

A radioactive formulation is also available as sodium iothalamate I-125 injection (brand name Glofil-125). It is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of people with kidney disease.[2]

  1. ^ a b c "Conray- iothalamate meglumine injection". DailyMed. 1 January 2021. Retrieved 23 February 2022.
  2. ^ a b "Glofil-125- sodium iothalamate i-125 injection injection, solution". DailyMed. 9 December 2019. Retrieved 23 February 2022.
  3. ^ "Cysto-Conray II- iothalamate meglumine injection". DailyMed. 31 December 2020. Retrieved 23 February 2022.